Reviewed,
UniProtKB/Swiss-Prot P33302 (PDR5_YEAST)
Last modified
November 25, 2008.
Version 97.
History...
Clusters with 100%,
90%,
50% identity |
Documents (2) |
Third-party data |
Customize display | text xml rdf/xml gff fasta |
Names and origin
| Protein names | Recommended name: Pleiotropic ABC efflux transporter of multiple drugs Alternative name(s): Pleiotropic drug resistance protein 5 Suppressor of toxicity of sporidesmin | ||||||
| Gene names |
| ||||||
| Organism | Saccharomyces cerevisiae (Baker's yeast) [Complete proteome] | ||||||
| Taxonomic identifier | 4932 [NCBI] | ||||||
| Taxonomic lineage | Eukaryota › Fungi › Dikarya › Ascomycota › Saccharomycotina › Saccharomycetes › Saccharomycetales › Saccharomycetaceae › Saccharomyces |
Protein attributes
| Sequence length | 1511 AA. |
| Sequence status | Complete. |
| Sequence processing | The displayed sequence is not processed. |
| Protein existence | Evidence at protein level. |
General annotation (Comments)
| Function | Active efflux of weakly charged organic compounds of 90 cubic Angstroms to 300 cubic Angstroms surface volume. Confers resistance to numerous chemicals including cycloheximide, sulfomethuron methyl, steroids, antiseptics, antibiotics, anticancer, herbicides, mycotoxins, insecticides, ionophores, alkaloids, flavonoids, phenothiazines, organotin compounds, carbazoles, lysosomotropic aminoesters, detergents, rhodamines and other fluorophores, azoles and other antifungals. Exhibits nucleoside triphosphatase activity. |
| Enzyme regulation | FK506, isonitrile, enniatin, RU49953, kitasatospora E420, staurosporine CGP42700, prenyl-flavonoids, D-octapeptides were found to be inhibitors in vivo. Vanadate and oligomycin were found to be inhibitors in vitro. |
| Subcellular location | Cell membrane; Multi-pass membrane protein. Note= The ERAD mutants 'Pro-183' and 'Tyr-1427' fail to reach the plasma membrane. The mutant 'Pro-183' accumulates into ER-associated compartments. |
| Induction | Expressed during exponential growth. Transcription is transiently activated within 40 min after induction by benomyl and other toxic chemicals. Multidrug resistance and PDR5 mRNA level are activated by the transcription regulators PDR1, PDR3, YAP1, YAP2, STB5 and by the mitochondrial rho zero mutation. Mutations or deletion in the PDR1 or PDR3 transcription factors strongly activate PDR5 mRNA and PDR5 translation. The transcription regulator RDR1 represses PDR5 expression. |
| Domain | The N-terminal ABC transporter domain (positions 161 to 410) contains degenerated Walker A and B ATP-binding motifs, suggesting that it may be less efficient in ATP binding or not functional at all. This is a distinctive feature of the PDR subfamily. The unusual length of the two extracellular loops at positions 686 to 774 and 1408 to 1476 is another specific feature of the PDR subfamily which may have an important role for function. |
| Post-translational modification | Ubiquitinylation mediates endocytosis and vacuolar degradation. Phosphorylation by casein kinase I stabilizes the protein half-life. |
| Biotechnological use | Strains lacking PDR5 are used for toxicity tests. Strains overexpressing PDR5 are used for screening antifungal sensitizers. |
| Miscellaneous | Present with 42000 molecules/cell in log phase SD medium in log phase SD medium. Full-sized PDR5 orthologs are found only in fungi and plants. Their topology and substrate specificity are distinct from mammalian MDR transporters. This protein has been 'adopted' by Andre Goffeau from the Catholic University of Louvain (Belgium). The above-mentioned scientist has agreed to help us to curate information available on this protein. We are grateful to that person for committing precious time to help producing annotation useful to the whole community. However that person is not responsible for any errors or omissions in this UniProtKB/Swiss-Prot entry. If you have found something wrong or missing in this entry you should submit an update report to: help@uniprot.org. |
| Sequence similarities | Belongs to the ABC transporter family. PDR subfamily. Contains 2 ABC transporter domains. |
| Biophysicochemical properties | Kinetic parameters: Activity measured in plasma membranes. KM=0.5 mM for MgATP Vmax=2.5 µmol/min/mg enzyme pH dependence: Optimum pH is 7.0. |
| Sequence caution | The sequence BAA05547.1 differs from that shown. Reason: Frameshift at position 61. |
Ontologies
Sequence annotation (Features)
| Feature key | Position(s) | Length | Description | Graphical view | Feature identifier | ||||
Molecule processing | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Chain | 1 – 1511 | 1511 | Pleiotropic ABC efflux transporter of multiple drugs | PRO_0000093442 | |||||
Regions | |||||||||
| Topological domain | 1 – 517 | 517 | Cytoplasmic Potential | ||||||
| Transmembrane | 518 – 542 | 25 | Potential | ||||||
| Topological domain | 543 – 558 | 16 | Extracellular Potential | ||||||
| Transmembrane | 559 – 579 | 21 | Potential | ||||||
| Topological domain | 580 – 611 | 32 | Cytoplasmic Potential | ||||||
| Transmembrane | 612 – 628 | 17 | Potential | ||||||
| Topological domain | 629 – 631 | 3 | Extracellular Potential | ||||||
| Transmembrane | 632 – 650 | 19 | Potential | ||||||
| Topological domain | 651 – 665 | 15 | Cytoplasmic Potential | ||||||
| Transmembrane | 666 – 685 | 20 | Potential | ||||||
| Topological domain | 686 – 774 | 89 | Extracellular Potential | ||||||
| Transmembrane | 775 – 793 | 19 | Potential | ||||||
| Topological domain | 794 – 1237 | 444 | Cytoplasmic Potential | ||||||
| Transmembrane | 1238 – 1260 | 23 | Potential | ||||||
| Topological domain | 1261 – 1291 | 31 | Extracellular Potential | ||||||
| Transmembrane | 1292 – 1313 | 22 | Potential | ||||||
| Topological domain | 1314 – 1324 | 11 | Cytoplasmic Potential | ||||||
| Transmembrane | 1325 – 1349 | 25 | Potential | ||||||
| Topological domain | 1350 – 1354 | 5 | Extracellular Potential | ||||||
| Transmembrane | 1355 – 1379 | 25 | Potential | ||||||
| Topological domain | 1380 – 1388 | 9 | Cytoplasmic Potential | ||||||
| Transmembrane | 1389 – 1407 | 19 | Potential | ||||||
| Topological domain | 1408 – 1476 | 69 | Extracellular Potential | ||||||
| Transmembrane | 1477 – 1499 | 23 | Potential | ||||||
| Topological domain | 1500 – 1511 | 12 | Cytoplasmic Potential | ||||||
| Domain | 161 – 410 | 250 | ABC transporter 1 | ||||||
| Domain | 869 – 1112 | 244 | ABC transporter 2 | ||||||
| Nucleotide binding | 905 – 912 | 8 | ATP Potential | ||||||
| Compositional bias | 784 – 787 | 4 | Poly-Phe | ||||||
Amino acid modifications | |||||||||
| Modified residue | 49 | 1 | Phosphothreonine | ||||||
| Modified residue | 54 | 1 | Phosphoserine | ||||||
| Modified residue | 58 | 1 | Phosphoserine | ||||||
| Modified residue | 59 | 1 | Phosphothreonine | ||||||
| Modified residue | 61 | 1 | Phosphoserine | ||||||
| Modified residue | 837 | 1 | Phosphoserine | ||||||
| Modified residue | 840 | 1 | Phosphoserine | ||||||
| Modified residue | 841 | 1 | Phosphoserine | ||||||
| Modified residue | 849 | 1 | Phosphoserine | ||||||
| Modified residue | 850 | 1 | Phosphoserine | ||||||
| Modified residue | 854 | 1 | Phosphoserine | ||||||
| Modified residue | 857 | 1 | Phosphotyrosine | ||||||
| Modified residue | 863 | 1 | Phosphoserine | ||||||
| Glycosylation | 734 | 1 | N-linked (GlcNAc...) Potential | ||||||
| Glycosylation | 1447 | 1 | N-linked (GlcNAc...) Potential | ||||||
| Cross-link | 825 | Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin) | |||||||
Experimental info | |||||||||
| Mutagenesis | 183 | 1 | L → P: Activates ER-associated degradation | ||||||
| Mutagenesis | 257 | 1 | T → I: Alters drug specificity | ||||||
| Mutagenesis | 302 | 1 | G → D: Confers generalized drug resistance | ||||||
| Mutagenesis | 648 | 1 | S → F: Alters drug specificity | ||||||
| Mutagenesis | 905 | 1 | G → S: Inactivates drug transport | ||||||
| Mutagenesis | 908 | 1 | G → S: Inactivates drug transport | ||||||
| Mutagenesis | 1009 | 1 | G → C: Confers generalized drug resistance | ||||||
| Mutagenesis | 1040 | 1 | G → D: Alters drug specificity | ||||||
| Mutagenesis | 1048 | 1 | S → V: Alters drug specificity | ||||||
| Mutagenesis | 1289 | 1 | E → K: Alters drug specificity | ||||||
| Mutagenesis | 1311 | 1 | Y → S: Alters drug specificity | ||||||
| Mutagenesis | 1360 | 1 | S → F: Alters drug specificity | ||||||
| Mutagenesis | 1393 | 1 | T → I: Alters drug specificity | ||||||
| Mutagenesis | 1427 | 1 | C → Y: Activates ER-associated degradation | ||||||
| Sequence conflict | 171 | 1 | N → L in BAA05547. Ref.1 | ||||||
| Sequence conflict | 190 | 1 | V → I in BAA05547. Ref.1 | ||||||
| Sequence conflict | 214 | 1 | D → T in BAA05547. Ref.1 | ||||||
| Sequence conflict | 308 | 1 | G → V in BAA05547. Ref.1 | ||||||
| Sequence conflict | 340 – 345 | 6 | Missing in BAA05547. Ref.1 | ||||||
| Sequence conflict | 476 | 1 | R → H in BAA05547. Ref.1 | ||||||
| Sequence conflict | 648 | 1 | Missing in BAA05547. Ref.1 | ||||||
| Sequence conflict | 770 | 1 | D → H in BAA05547. Ref.1 | ||||||
Sequences
| ||||||||||||||||||
References
| « Hide 'large scale' references | |
| [1] | "Saccharomyces cerevisiae YDR1, which encodes a member of the ATP-binding cassette (ABC) superfamily, is required for multidrug resistance." Hirata D., Yano K., Miyahara K., Miyakawa T. Curr. Genet. 26:285-294(1994) [PubMed: 7882421] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [GENOMIC DNA]. Strain: ATCC 38626 / AH22 / NRRL Y-12843. |
| [2] | "PDR5, a novel yeast multidrug resistance conferring transporter controlled by the transcription regulator PDR1." Balzi E., Wang M., Leterme S., van Dyck L., Goffeau A. J. Biol. Chem. 269:2206-2214(1994) [PubMed: 8294477] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [GENOMIC DNA], PARTIAL PROTEIN SEQUENCE, TOPOLOGY, DOMAINS. Strain: ATCC 204508 / S288c. |
| [3] | "Molecular cloning and expression of the Saccharomyces cerevisiae STS1 gene product. A yeast ABC transporter conferring mycotoxin resistance." Bissinger P.H., Kuchler K. J. Biol. Chem. 269:4180-4186(1994) [PubMed: 8307980] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [GENOMIC DNA]. Strain: ATCC 204510 / AB320. |
| [4] | "Analysis of a 35.6 kb region on the right arm of Saccharomyces cerevisiae chromosome XV." Bordonne R., Camasses A., Madania A., Poch O., Tarassov I.A., Winsor B., Martin R.P. Yeast 13:73-83(1997) [PubMed: 9046089] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [GENOMIC DNA]. Strain: S288c / FY1678. |
| [5] | "The nucleotide sequence of Saccharomyces cerevisiae chromosome XV." Dujon B., Albermann K., Aldea M., Alexandraki D., Ansorge W., Arino J., Benes V., Bohn C., Bolotin-Fukuhara M., Bordonne R., Boyer J., Camasses A., Casamayor A., Casas C., Cheret G., Cziepluch C., Daignan-Fornier B., Dang V.-D. Kleine K.Nature 387:98-102(1997) [PubMed: 9169874] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. Strain: S288c / FY1678. |
| [6] | "The multidrug resistance gene PDR1 from Saccharomyces cerevisiae." Balzi E., Chen W., Ulaszewski S., Capieaux E., Goffeau A. |

Clusters with